Loading clinical trials...
Loading clinical trials...
Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With Upadacitinib (ABT-494)
Conditions
Interventions
Upadacitinib
Pneumococcal 13-valent conjugate vaccine (PCV-13)
Locations
124
United States
Rheum Assoc of North Alabama /ID# 135926
Huntsville, Alabama, United States
AZ Arthritis and Rheumotology Research, PLLC /ID# 135902
Phoenix, Arizona, United States
AZ Arthritis and Rheumotology Research, PLLC /ID# 135931
Phoenix, Arizona, United States
C.V. Mehta MD, Med Corporation /ID# 124092
Hemet, California, United States
Moores Cancer Center at UC San Diego /ID# 128747
La Jolla, California, United States
Desert Medical Advances - Palm Desert /ID# 135911
Palm Desert, California, United States
Start Date
January 24, 2014
Primary Completion Date
July 29, 2021
Completion Date
July 29, 2021
Last Updated
July 12, 2022
NCT07536529
NCT06329401
NCT07048197
NCT06647069
NCT07484243
NCT06841562
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions